Skip to main content

Year: 2019

Aspo Plc – Managers’ transactions – Risto Salo

Aspo PlcManagers’ transactionsDecember 5, 2019 at 13:30 Aspo Plc – Managers’ transactions – Risto SaloPerson subject to the notification requirementName: Risto SaloPosition: Member of the Board/Deputy member(X) Legal personIssuer: Aspo OyjLEI: 7437000TB0GHDHLPX677Notification type: INITIAL NOTIFICATIONReference nymber: 7437000TB0GHDHLPX677_20191204175545_4____________________________________________Transaction date: 2019-12-02Venue: NASDAQ HELSINKI LTD (XHEL)Instrument type: SHAREISIN: FI0009008072Nature of the transaction: AQCUISITION(X) Made under life insurance policyTransaction details(1): Volume: 6 500 Unit price: 7.76 EURAggregated transactions(1): Volume: 6 500 Volume weighted average price: 7.76 EURASPO PlcFor further information, please contact: Arto Meitsalo, CFO, tel. +358 40 551 1422, arto.meitsalo@aspo.com

Continue reading

Aspo Oyj – Johdon liiketoimet – Risto Salo

Aspo OyjJohtohenkilöiden liiketoimet5.12.2019 klo 13.30 Aspo Oyj  – Johdon liiketoimet – Risto SaloIlmoitusvelvollinenNimi: Risto SaloAsema: Hallituksen jäsen/varajäsen(X) OikeushenkilöLiikkeeseenlaskija: Aspo OyjLEI: 7437000TB0GHDHLPX677Ilmoituksen luonne: ENSIMMÄINEN ILMOITUSViitenumero: 7437000TB0GHDHLPX677_20191204175545_4____________________________________________Liiketoimen päivämäärä: 2019-12-02Kauppapaikka: NASDAQ HELSINKI LTD (XHEL)Instrumenttityyppi: OSAKEISIN: FI0009008072Liiketoimen luonne: HANKINTA(X) Liiketoimi on toteutettu henkivakuutuksen yhteydessäLiiketoimien yksityiskohtaiset tiedot(1): Volyymi: 6 500 Yksikköhinta: 7,76 EURLiiketoimien yhdistetyt tiedot(1): Volyymi: 6 500 Keskihinta: 7,76 EURASPO OYJLisätietoja:Arto Meitsalo, talousjohtaja,  puh. 040 551 1422, arto.meitsalo@aspo.com

Continue reading

Capital Power announces slate of strategic investments

EDMONTON, Alberta, Dec. 05, 2019 (GLOBE NEWSWIRE) — Capital Power Corporation (TSX: CPX) (“Capital Power” or “the Company”) is pleased to deliver on its commitment to create dependable, cost-effective and innovative electricity solutions to power a sustainable future. In support of our sustainability targets, we are taking the next steps to transform power generation through the utilization of world-leading carbon conversion technology and the strategic integration of natural gas and renewables. At our 11th annual Investor Day held in Toronto today, we will provide an update on these topics, as well as our growth outlook, value creation in operations and construction, sustainability strategy and our operational and financial targets for 2020.“Capital Power continues to execute on its renewables growth strategy with the 202 megawatt...

Continue reading

EVO Payments Announces Proposed Offering of Common Stock

ATLANTA, Dec. 05, 2019 (GLOBE NEWSWIRE) — EVO Payments, Inc. (NASDAQ: EVOP) (“EVO” or the “Company”) announced today a proposed underwritten offering of 4,500,000 shares of its Class A common stock. The Company intends to use all of the net proceeds received by the Company from the sale of shares of its Class A common stock in the proposed offering to purchase LLC interests in EVO Investco, LLC (“EVO LLC”) and an equivalent number of shares of the Company’s Class B common stock (which shares will then be cancelled) from Blueapple, Inc., as well as LLC interests in EVO LLC and an equivalent number of shares of the Company’s Class D common stock (which shares will then be cancelled) from entities affiliated with Madison Dearborn Partners, LLC.J.P. Morgan and Barclays are acting as joint underwriters for the proposed offering.The offering...

Continue reading

Centogene reporting its financial results for the three months and nine months ended September 30, 2019

CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, Dec. 05, 2019 (GLOBE NEWSWIRE) — CENTOGENE N.V. (Nasdaq: CNTG), a commercial-stage company focused on rare diseases that transforms real-world clinical and genetic data into actionable information for patients, physicians and pharmaceutical companies, announced today a corporate update and reported financial results for the third quarter and the nine months ended September 30, 2019.Recent Corporate HighlightsOn November 7, 2019, Centogene completed a corporate reorganization in connection with an initial public offering in the United States, and Centogene N.V. (“the Company”) became the holding company of Centogene AG, and the ultimate parent company of the group.  On the same day, Centogene N.V.’s shares began trading on the Nasdaq Global Market, after pricing an initial public...

Continue reading

Referat vedrørende ekstraordinær generalforsamling i Dalhoff Larsen & Horneman A/S

SelskabsmeddelelseNr. 15/2019Referat vedrørende ekstraordinær generalforsamling i Dalhoff Larsen & Horneman A/SDLH A/S har afholdt ekstraordinær generalforsamling den 5. december 2019 med følgende dagsorden:Forslag om godkendelse af den betingede aftale om salg af alle driftsmæssige aktiviteterForslag om godkendelse af at den registrerede direktør og Selskabets medarbejdere kan differenceafregne deres warrants samt sælge deres stamaktierForslag om godkendelse af vederlag til udvalgte bestyrelsesmedlemmerForslag om godkendelse af ændring af Selskabets vedtægter, herunder Selskabets navn, sletning af binavne, ændring af sted for afholdelse af generalforsamlinger og ændring af tegningsregelForslag om bemyndigelse til dirigenten.Bestyrelsen havde i henhold til vedtægternes pkt. 9.1 udpeget advokat Søren Ingerslev som dirigent for den ekstraordinære...

Continue reading

Algernon Pharmaceuticals’ NP-120 (Ifenprodil) Outperforms Merck’s Phase 3 Drug MK-7264 (Gefapixant) in an Acute Cough Study by 110%

VANCOUVER, British Columbia, Dec. 05, 2019 (GLOBE NEWSWIRE) — Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCB: BTHCF) (the “Company” or “Algernon”), a clinical stage pharmaceutical development company, is pleased to announce that NP-120 (Ifenprodil), its repurposed lead candidate for the treatment of idiopathic pulmonary fibrosis (IPF), showed dramatic superiority over Gefapixant, Merck’s lead phase 3 trial drug, in a well accepted acute cough in-vivo animal study.Pharmidex, a contract research organization (CRO) and a global leader in respiratory research conducted the in-vivo cough study using the guinea pig citric acid challenge model. Data from this recent study demonstrated that at clinically relevant doses: Ifenprodil (1.5 mg/kg) showed a reduction of 42% in mean cough frequency vs untreated control (p

Continue reading

KLX Energy Services Financial Results for Third Quarter Ended October 31, 2019; Implements Major Cost Reduction Program; Strong Third Quarter Cash Flow

WELLINGTON, Fla., Dec. 05, 2019 (GLOBE NEWSWIRE) — KLX Energy Services Holdings, Inc. (“KLX Energy Services” or the “Company”) (NASDAQ: KLXE), a leading U.S. onshore provider of mission critical, asset light oilfield services, today reported its third fiscal quarter ended October 31, 2019 financial results.The oilfield services industry experienced an abrupt deterioration in demand during the three-month period ended October 31, 2019. As previously reported, the Company responded to the decline in demand, which accelerated through the end of our third quarter, with contemporaneous cost reductions in all aspects of the Company’s business. As a result of these and other measures, we incurred a charge of approximately $13 million, of which approximately $11 million were non-cash costs. Additionally, as a result of the rapid deterioration...

Continue reading

Svensk Hypotekspension Fond 3 AB (publ) – Early redemption of notes

Press release 5 December 2019Svensk Hypotekspension Fond 3 AB (publ) – Early redemption of notesSvensk Hypotekspension Fond 3 AB (publ) (the “Issuer”) informs that it intends to voluntarily redeem the SEK 2,000,000,000 Mortgage Backed Fixed Rate Notes with ISIN SE0007691621 (the “Notes”) before the first call date in accordance with the terms and conditions originally dated 6 February 2016 and as amended and restated 27 November 2019 (the “Terms and Conditions”). All outstanding Notes will be redeemed in full at their nominal amount, together with accrued but unpaid interest and an early call premium. The redemption date is expected to be 17 December 2019 (the “Redemption Date”).A notice of early redemption will today be circulated to the holders of the Notes and will be published on the website of the Issuer. The notice will be irrevocable...

Continue reading

Svensk Hypotekspension Fond 3 AB (publ) – Tidig inlösen av obligation

Pressmeddelande den 5 december 2019Svensk Hypotekspension Fond 3 AB (publ) – Tidig inlösen av obligationSvensk Hypotekspension Fond 3 AB (publ) (”Emittenten”) informerar att de avser att frivilligt lösa in de SEK 2 000 000 000 bolånesäkrade fastränteobligationerna med ISIN SE0007691621 (”Obligationerna”) före den första inlösendagen i enlighet med obligationsvillkoren, ursprungligen daterade den 6 februari 2016 och såsom ändrade och reviderade den 27 november 2019 (”Villkoren”). Samtliga utestående Obligationer kommer att lösas in till sitt nominella belopp, tillsammans med upplupen men obetald ränta och en premie för tidigt inlösen. Inlösendagen förväntas vara den 17 december 2019 (”Inlösendagen”).Ett meddelande om tidig inlösen kommer idag att cirkuleras till innehavare av Obligationerna och meddelandet kommer att publiceras på Emittentens...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.